APOTEX CORP. for APOTEX CORP.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report | Jan 22, 2024 | $530,000 | Replaced |
| 4th Quarter - Report (this page) | Jan 22, 2024 | $530,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Federal policy relating to the approval of generic versions of pharmaceutical inhalation products; and Federal policy relating to DEA quotas and the availability of generic ADHD medicines
Foreign entity interest: Apotex Pharmaceutical Holdings Inc., Artemis Intermediate Holdings Inc., and Artemis Parent Inc., the parent companies of Apotex Corp. identified by the registrants third quarter 2023 LD-2, have direct or indirect interests in companies that manufacture and or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Manufacturing MAN
S. 2510, the RAPID Reserve Act, provisions relating to awarding contracts to US or OECD based generic drug manufacturers to establish a reserve of essential medicines; and Federal policy relating to addressing drug shortages and strengthening domestic pharmaceutical manufacturing capabilities.
Foreign entity interest: Apotex Pharmaceutical Holdings Inc., Artemis Intermediate Holdings Inc., and Artemis Parent Inc., the parent companies of Apotex Corp. identified by the registrants third quarter 2023 LD-2, have direct or indirect interests in companies that manufacture and or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.